Brush Up on LMWH Dosing in Special Populations

November 2024

Questions still come up about low-molecular-weight heparin (LMWH) doses for venous thromboembolism (VTE) in special populations.

We’re using a subcutaneous LMWH, such as enoxaparin, less often now that direct oral anticoagulants (DOACs) are usually preferred.

But when a LMWH is needed, dosing can be tricky in patients with renal impairment, obesity, or who are underweight.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote